| Literature DB >> 24793406 |
Shanshan Li1, Qingfeng Xie1, Yuqun Zeng2, Chuan Zou2, Xusheng Liu2, Shouhai Wu1, Haixia Deng1, Yang Xu1, Xian C Li3, Zhenhua Dai1.
Abstract
Despite extensive studies on CD4(+)CD25(+) regulatory T cells (Tregs) during the past decade, the progress on their clinical translation remains stagnant. Mounting evidence suggests that naturally occurring CD8(+)CD122(+) T cells are also Tregs with the capacity to inhibit T-cell responses and suppress autoimmunity as well as alloimmunity. In fact, they are memory-like Tregs that resemble a central memory T cell (TCM) phenotype. The mechanisms underlying their suppression are still not well understood, although they may include IL-10 production. We have recently demonstrated that programmed death-1 (PD-1) expression distinguishes between regulatory and memory CD8(+)CD122(+) T cells and that CD8(+)CD122(+) Tregs undergo faster homeostatic proliferation and are more potent in the suppression of allograft rejection than conventional CD4(+)CD25(+) Tregs. These findings may open a new line of investigation for accelerating effective Treg therapies in the clinic. In this review, we summarize the significant progress in this promising field of CD8(+)CD122(+) Treg research and discuss their phenotypes, suppressive roles in autoimmunity and alloimmunity, functional requirements, mechanisms of action and potential applications in the clinic.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24793406 PMCID: PMC4085522 DOI: 10.1038/cmi.2014.25
Source DB: PubMed Journal: Cell Mol Immunol ISSN: 1672-7681 Impact factor: 11.530